NCT05218499 2026-03-02
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 2/3 Completed
Clinical Trials
102 trialsNCT01231906 2026-01-23
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Children's Oncology Group
Phase 3 Completed
NCT05858710 2025-07-28
Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma
Thermosome GmbH
Phase 1 Completed
NCT02451943 2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3 Completed
NCT03277924 2024-08-13
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Completed
NCT02049905 2024-06-13
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
ImmunityBio, Inc.
Phase 3 Completed
NCT01514188 2024-05-29
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
ImmunityBio, Inc.
Phase 2 Completed
NCT01459484 2024-05-20
ISG/OS-2
Italian Sarcoma Group
Phase 2 Completed
NCT03056001 2023-11-18
Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT02584309 2023-11-07
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Phase 2 Completed
NCT03009201 2023-08-16
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
OHSU Knight Cancer Institute
Phase 1 Completed
NCT00667342 2023-08-07
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00006734 2023-08-03
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
Children's Oncology Group
Phase 3 Completed
NCT03317457 2023-06-15
MEDISARC
AIO-Studien-gGmbH
Phase 2 Completed
NCT00134030 2023-06-07
EURAMOS-1
Children's Oncology Group
Phase 3 Completed
NCT00346125 2022-12-15
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT02063022 2022-09-19
EW-1
Italian Sarcoma Group
Phase 3 Completed
NCT02727387 2022-09-19
EW-2
Italian Sarcoma Group
Phase 2 Completed
NCT00346164 2022-04-28
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Children's Oncology Group
Phase 3 Completed
NCT02076620 2022-04-04
L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Philogen S.p.A.
Phase 1 Completed
NCT03042819 2021-12-09
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
University Health Network, Toronto
Phase 1 Completed
NCT00000987 2021-11-04
A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Completed
NCT00000996 2021-11-04
A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT00000681 2021-11-03
A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Completed
NCT00000954 2021-10-29
A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Completed
NCT02888665 2021-05-26
Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT02448537 2021-03-03
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Massachusetts General Hospital
Phase 2 Completed
NCT03283696 2020-09-10
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT01446809 2020-04-13
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
University of Washington
Phase NA Completed
NCT00354744 2020-01-29
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Children's Oncology Group
Phase 3 Completed
NCT02326025 2019-11-21
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT01375699 2019-08-26
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers
Virginia Commonwealth University
Phase 1 Completed
NCT02783599 2019-08-12
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT00061893 2019-02-15
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Children's Oncology Group
Phase 2 Completed
NCT00283621 2018-11-07
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide
M.D. Anderson Cancer Center
Phase NA Completed
NCT00662233 2018-10-09
Combination Chemotherapy in Treating Patients With Sarcoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00304083 2018-09-18
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00484341 2018-08-29
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
AGC Biologics S.p.A.
Phase 2 Completed
NCT00722293 2017-11-13
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01055314 2017-08-29
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01861951 2017-08-21
EPAZ
Hannover Medical School
Phase 2 Completed
NCT00043979 2017-05-31
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01185964 2017-04-14
A Study of Olaratumab in Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1/2 Completed
NCT00002492 2016-12-15
Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma
University of Miami
Phase 2 Completed
NCT02986503 2016-12-08
EUROBOSS
Italian Sarcoma Group
Completed
NCT01605526 2016-11-02
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Hoffmann-La Roche
Phase 1 Completed
NCT01440088 2016-06-02
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Threshold Pharmaceuticals
Phase 3 Completed
NCT00720174 2016-05-17
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01490060 2016-04-11
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
M.D. Anderson Cancer Center
Phase NA Completed
NCT00586846 2016-01-20
Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed